G1 Therapeutics to Participate in Four Investor Conferences in September 2020
G1 Therapeutics (GTHX) has announced its participation in several investor conferences in September 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics (GTHX) has announced its participation in several investor conferences in September 2020. Key events include the Citi 15th Annual BioPharma Virtual Conference on September 10, the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 12:00 p.m. ET, and the Cantor Global Virtual Healthcare Conference on September 15 at 8:40 a.m. ET. Additionally, the Morgan Stanley 18th Annual Global Healthcare Conference will take place on September 16 at 4:15 p.m. ET. For live and archived presentations, visit G1's Events & Presentations page.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was +6.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will participate in the following investor conferences in September 2020:
- Citi 15th Annual BioPharma Virtual Conference: G1 will host investor meetings at the conference on Thursday, September 10, 2020.
- H.C. Wainwright 22nd Annual Global Investment Conference: Chief Financial Officer Jennifer Moses will present a company update on Monday, September 14, 2020 at 12:00 p.m. ET.
- 2020 Cantor Global Virtual Healthcare Conference: Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company update on Tuesday, September 15, 2020 at 8:40 a.m. ET.
- Morgan Stanley 18th Annual Global Healthcare Conference: Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company update on Wednesday, September 16, 2020 at 4:15 p.m. ET.
To access live and archived webcasts of the presentations, please visit the Events & Presentations page of the G1 website.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contact:
Jeff Macdonald
G1 Therapeutics, Inc.
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.